The Generative AI Lab for the Life Sciences
Converge Bio is an AI-driven drug discovery company founded in 2024 and headquartered in Tel Aviv, Israel with a presence in Boston, Massachusetts. The company provides a generative AI lab for life sciences, helping pharmaceutical and biotech customers accelerate drug development through AI-powered molecule design, discovery, and manufacturing optimization. Founded by CEO Dov Gertz, CTO Oded Kalev, and CSO Iddo Weiner, Converge Bio raised a $5.5M seed in 2024 and a $25M Series A in January 2026 led by Bessemer Venture Partners. The company has completed over 40 programs with more than a dozen pharma and biotech clients globally.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2025
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...
